Drugs in Dev. Immunology
Phase I
India 
Lead Product(s) : Abatacept
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Abatacept is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Arthritis, Rheumatoid.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
November 13, 2023
Lead Product(s) : Abatacept
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tocilizumab
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tocilizumab Biosimilar is a recombinant humanized monoclonal antibody targeting IL-6R, which specifically binds to sIL-6R and mIL-6R and inhibits signaling mediated by sIL-6R or mIL-6R. It is approved for the treatment of RA, sJIA, and CRS.
Product Name : DRL_TC
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 05, 2023
Lead Product(s) : Tocilizumab
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tocilizumab
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Dr. Reddy’s Successfully Completes Phase 1 Study Of DRL_TC, a Proposed Biosimilar of Tocilizumab
Details : Tocilizumab is an important anti-rheumatic agent used in the treatment of adult patients with moderate to severe active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
Product Name : DRL_TC
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
December 19, 2022
Lead Product(s) : Tocilizumab
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Itolizumab
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Equillium
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Study for Itolizumab in Lupus Nephritis Initiated in India, Post DCGI Approval
Details : ALZUMAb-L (Itolizumab), an anti-CD6 monoclonal antibody targets CD6-ALCAM pathway, commercialized in India since 2013 for plaque psoriasis, and emergency use authorization in COVID-19. Equillium has expanded its EQUALISE study in Systemic Lupus Erythemat...
Product Name : Alzumab
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
December 23, 2021
Lead Product(s) : Itolizumab
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Equillium
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cefepime
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Clinartis
Deal Size : Inapplicable
Deal Type : Inapplicable
To Investigate the Multiple Dose Safety, Tolerability and Pharmacokinetics of WCK 4282 (FEP-TAZ)
Details : Cefepime is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Drug Hypersensitivity.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
August 09, 2018
Lead Product(s) : Cefepime
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Clinartis
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
